WO2006013750A1 - Matiere alimentaire ayant un effet de regulation du metabolisme des lipides, aliment dietetique, nourriture pour animaux et procede pour nourrir un animal - Google Patents

Matiere alimentaire ayant un effet de regulation du metabolisme des lipides, aliment dietetique, nourriture pour animaux et procede pour nourrir un animal Download PDF

Info

Publication number
WO2006013750A1
WO2006013750A1 PCT/JP2005/013630 JP2005013630W WO2006013750A1 WO 2006013750 A1 WO2006013750 A1 WO 2006013750A1 JP 2005013630 W JP2005013630 W JP 2005013630W WO 2006013750 A1 WO2006013750 A1 WO 2006013750A1
Authority
WO
WIPO (PCT)
Prior art keywords
residue
defatted
weight
animal
animal feed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2005/013630
Other languages
English (en)
Japanese (ja)
Inventor
Hideki Ushio
Kazuyuki Ohara
Tomoteru Yamasaki
Shigeharu Kanemoto
Hiroyuki Maehara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Satake Engineering Co Ltd
Satake Corp
Tokyo University of Marine Science and Technology NUC
Original Assignee
Satake Engineering Co Ltd
Satake Corp
Tokyo University of Marine Science and Technology NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Satake Engineering Co Ltd, Satake Corp, Tokyo University of Marine Science and Technology NUC filed Critical Satake Engineering Co Ltd
Priority to JP2006531398A priority Critical patent/JP4785140B2/ja
Publication of WO2006013750A1 publication Critical patent/WO2006013750A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A23K10/37—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms from waste material
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/115—Cereal fibre products, e.g. bran, husk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
    • Y02P60/87—Re-use of by-products of food processing for fodder production

Definitions

  • the present invention relates to a food material having a lipid metabolism regulating action and useful for preventing and improving obesity and lifestyle-related diseases, a health food, an animal feed, and a method for raising an animal fed with this animal feed. Is.
  • rice bran contains a large amount of vegetable oil
  • rice bran is used in large amounts as a raw material for cooking oil.
  • Rice bran contains various nutrients such as vitamins, minerals and dietary fiber, and also contains a large amount of useful ingredients with various physiologically active functions. It is widely used as a raw material for feed additives.
  • rice bran is used as a raw material for edible oil or when pharmaceuticals, food additives, feed additives, etc. are made from rice bran extract, rice bran koji and other products are extracted and then defatted rice bran ( A large amount of residue left after removal of oil with an organic solvent, etc., and residue (after removal of water-soluble components such as defatted residue).
  • Patent Document 1 Japanese Patent Laid-Open No. 2001-327881
  • Patent Document 2 JP 05-194069
  • Patent Document 3 JP 05-199201 A
  • a problem to be solved is that a large amount of defatted soot and residue are not effectively used. [0007] Therefore, the present inventors have intensively studied defatted lees and residues, and defatted lees and residues still have useful components, particularly components that have a function of regulating lipid metabolism in humans and animals, That is, it was discovered that a component having an action of increasing blood adiponectin concentration or lowering insulin resistance was considerably contained, and the present invention was made.
  • the present invention focuses on the components remaining in defatted lees and residues, and regulates lipid metabolism in humans and animals to prevent or improve obesity and lifestyle-related diseases. Main features.
  • the food material having a lipid metabolism regulating action according to the present invention is characterized in that it comprises defatted or residue.
  • the health food having a lipid metabolism regulating action according to the present invention is characterized in that defatted koji or residue is one of the components.
  • the lipid metabolism regulating action refers to an action that activates lipid metabolism in the human body or animal body to prevent or eliminate fattening and to prevent or eliminate lifestyle-related diseases.
  • food materials are not only materials that can be consumed by humans, but also materials that can be used by animals for feed.
  • the defatted koji is a koji that is obtained when kneading cereals.
  • the degreasing strength also refers to the remaining residue obtained by extracting water-soluble components with water.
  • the defatted residue or residue includes a fraction having an effect of increasing blood adiponectin concentration or decreasing insulin resistance.
  • this fraction include hydroxycinnamic acid analog plant sterol esters. be able to.
  • defatted lees and residues do not differ greatly in the effects of anti-obesity and anti-lifestyle diseases, and therefore the lees added to animal feed may be defatted lees or residues.
  • the animal feed having a lipid metabolism regulating action according to the present invention is characterized in that defatted koji or residue is one of the components.
  • the animal breeding method according to the present invention is characterized in that the animal is fed by feeding the animal feed using defatted straw or residue as one of the components.
  • the basic components of the animal feed may be substantially the same as the animal feed generally used.
  • the animal feed preferably contains a certain amount of lipid to improve eating.
  • Lipids are included in feed raw materials from the beginning, and include fats and oils and fats and oils to which aftertaste is also added.
  • the oils and fats added later include, for example, rapeseed oil, soybean oil, corn oil, palm oil, castor oil, lard, beef tallow, fish oil, whale oil, or one or more mixed oils selected from these oils. Can be mentioned.
  • Animal feeds containing lipids contain 1 to 20% by weight of lipids and 1 to 15% by weight of defatted straw or residue (active ingredient hydroxycinnamic acid analog plant sterol esters As for the amount, about 20 to 300 / zg per lOOg of feed) can be mentioned.
  • the reason why the lipid content is limited to 1 to 20% by weight is that if the lipid content is less than 1% by weight, the bite of pets and livestock becomes worse and the lipid content exceeds 20% by weight. It is the power that makes it difficult to form pellets as feed.
  • the reason why the defatted residue or residue is limited to 1 to 15% by weight is that if the defatted residue or residue is less than 1% by weight, the anti-obesity effect or the residue is less than 15% by weight. If it exceeds the limit, other essential ingredients become too small, resulting in a feed with a poor nutritional balance. However, if the defatted lees or residue is 1 to 15% by weight, the nutritional balance is good and anti-obesity and anti-lifestyle-related diseases are effective. This is because
  • the edible fats and oils are used as the lipids described above from the viewpoint that the effects of anti-obesity and anti-life-style related diseases are obtained in the animal feed and the animal breeding method having a lipid metabolism regulating action according to the present invention.
  • the defatted lees or residues include a fraction having an effect of increasing blood adiponectin concentration or an effect of decreasing insulin resistance.
  • this fraction include hydroxycinnamic acid analog plant sterol esters. This is the same as in the case of food materials and health foods described above.
  • the invention's effect [0022] According to the present invention, it is possible to effectively use defatted lees and residues that have not been effectively used until now as raw materials for food ingredients, health foods, animal feeds, and the like. is there.
  • a highly safe food material, health food, and the like that can improve the obesity of human beings, pets or livestock, and can prevent or improve lifestyle-related diseases such as diabetes. There is an effect that animal feed can be provided at low cost.
  • FIG. 1 is a graph showing the relationship between residue content (% by weight) and blood adiponectin level (g / ml).
  • FIG. 2 is a graph showing the relationship between residue content (% by weight) and obesity level (X 10 ′′ 2 g / m 2 ).
  • FIG. 3 is a graph showing the effect of various components on adiponectin secretion in mouse 3T3-L1 adipocytes.
  • FIG. 4 is a graph showing the HOMA insulin resistance index of mice used in the test.
  • FIG. 5 is a graph showing the content (mg) of hydroxycinnamic acid analog plant sterol esters in 1 kg of rice bran and residue.
  • FIG. 6 is a graph showing the content (mg) of hydroxycinnamic acid analog plant sterol esters in 1 kg of total lipid of rice bran and residue.
  • mice were examined.
  • An ELIS A measurement kit (Otsuka Pharmaceutical) was used for measurement of blood adiponectin levels.
  • 3T3-L1 fibroblasts were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) to reach confluence, then 1 ⁇ dexamethasone, 0.5 mM isobutyl. Differentiation was induced with 10% FB S DMEM containing methylxanthine and 5 / z gZml insulin.
  • DMEM Dulbecco's modified Eagle's medium
  • FBS fetal bovine serum
  • hydroxycinnamic acid analog plant sterol ester significantly increased adiponectin secretion in 3T3-L1 adipocytes (P ⁇ 0. 01). ).
  • other plant sterols, ferulic acid and cholesterol-added cocoon plots were stronger than the control plots.
  • the active ingredients in the present invention are hydroxycinnamic acid analog plant sterol esters. it was thought.
  • C57BL / 6Jcl mice were given a feed containing 5% residue and 10% edible oil or fat, or a feed containing no residue containing only 10% edible oil and fat. I was reared. Then, glucose was orally administered to each of these 5 mice, and blood glucose content and insulin level were quantified. The HOMA-IR index (insulin level before glucose load X blood glucose concentration Z22.5), which is an index of insulin resistance, was calculated using the results of this quantification. The results were as shown in the graph of FIG.
  • Blood glucose was quantified using a glucose CII test kit from Wako Pure Chemical Industries, Ltd., and insulin was quantified using a Levis Insulin Mouse ELISA kit from Shibayagi Co., Ltd.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Animal Husbandry (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)

Abstract

L'invention concerne une matière alimentaire tout à fait sans danger, laquelle peut améliorer la tendance à l'obésité chez des humains, des animaux domestiques ou du bétail et peut donc prévenir ou améliorer des maladies liées au mode de vie telles que le diabète, un aliment diététique et une nourriture pour animaux à bas prix. On utilise le son de riz dégraissé ou le résidu de son de riz, lesquels contiennent des fractions contenant des esters de cholestérol végétal et d'analogues de l'acide hydroxycinnamique, etc., ayant un effet de régulation du métabolisme des lipides, comme matière première pour un aliment diététique ou une nourriture pour animaux. Dans le cas où l'aliment diététique ou la nourriture pour animaux contient de 1 à 20 % en poids de lipides, il est préférable que la teneur du son de riz dégraissé ou du résidu de son de riz aille de 1 à 15 % en poids.
PCT/JP2005/013630 2004-08-04 2005-07-26 Matiere alimentaire ayant un effet de regulation du metabolisme des lipides, aliment dietetique, nourriture pour animaux et procede pour nourrir un animal Ceased WO2006013750A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006531398A JP4785140B2 (ja) 2004-08-04 2005-07-26 脂質代謝調節作用を有する食品素材、健康食品、動物用飼料及び動物の飼育方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004-227822 2004-08-04
JP2004227822 2004-08-04

Publications (1)

Publication Number Publication Date
WO2006013750A1 true WO2006013750A1 (fr) 2006-02-09

Family

ID=35787040

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/013630 Ceased WO2006013750A1 (fr) 2004-08-04 2005-07-26 Matiere alimentaire ayant un effet de regulation du metabolisme des lipides, aliment dietetique, nourriture pour animaux et procede pour nourrir un animal

Country Status (2)

Country Link
JP (1) JP4785140B2 (fr)
WO (1) WO2006013750A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008099448A1 (fr) * 2007-02-09 2008-08-21 Masayoshi Yamaguchi Agent préventif/thérapeutique pour les maladies diabétiques
JP2011063554A (ja) * 2009-09-18 2011-03-31 Tokyo Univ Of Marine Science & Technology アディポネクチン分泌調節剤
US9943517B2 (en) 2012-11-13 2018-04-17 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
US10076507B1 (en) 2011-07-15 2018-09-18 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014149280A1 (fr) * 2013-03-15 2014-09-25 Nusirt Sciences, Inc. Traitement d'animaux domestiques comportant des activateurs de sirtuine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0725779A (ja) * 1993-06-25 1995-01-27 Yakurigaku Chuo Kenkyusho:Kk 脱脂米胚芽由来のリパーゼインヒビター
JP2001097880A (ja) * 1999-09-28 2001-04-10 Otsuka Pharmaceut Factory Inc 脱脂糠由来のリパーゼ阻害物質
JP2002316939A (ja) * 2001-04-18 2002-10-31 Real:Kk α−グルコシダーゼ阻害剤及びそれを含む加工食品、過血糖症用剤、飼料並びに添加剤
JP2004091462A (ja) * 2002-09-02 2004-03-25 Oriza Yuka Kk 糖質吸収阻害剤
JP2005068132A (ja) * 2003-08-06 2005-03-17 Enkaku Iryo Kenkyusho:Kk アディポネクチン分泌促進剤、並びに該アディポネクチン分泌促進剤を含有する抗動脈硬化剤、抗肥満剤、抗糖尿病剤、食品添加剤、機能性食品及び飼料添加剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0725779A (ja) * 1993-06-25 1995-01-27 Yakurigaku Chuo Kenkyusho:Kk 脱脂米胚芽由来のリパーゼインヒビター
JP2001097880A (ja) * 1999-09-28 2001-04-10 Otsuka Pharmaceut Factory Inc 脱脂糠由来のリパーゼ阻害物質
JP2002316939A (ja) * 2001-04-18 2002-10-31 Real:Kk α−グルコシダーゼ阻害剤及びそれを含む加工食品、過血糖症用剤、飼料並びに添加剤
JP2004091462A (ja) * 2002-09-02 2004-03-25 Oriza Yuka Kk 糖質吸収阻害剤
JP2005068132A (ja) * 2003-08-06 2005-03-17 Enkaku Iryo Kenkyusho:Kk アディポネクチン分泌促進剤、並びに該アディポネクチン分泌促進剤を含有する抗動脈硬化剤、抗肥満剤、抗糖尿病剤、食品添加剤、機能性食品及び飼料添加剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"BOSO Yushi, Shin Yushi no Tokusei to Oyo Kome Abura (sono 2)", YUSHI, vol. 51, no. 1, 1998, pages 76 - 81, XP002997747 *
TSUJIWAKI S.: "Komenuka Seibun no Seiri Kassei Kino", SHOKUHIN TO KAGAKU, vol. 43, no. 8, 2001, pages 75 - 80, XP002997749 *
YAMASAKI T. ET AL: "Defatted rice bran intake raises serum adiponectin levels in mouse", SEIKAGAKU, vol. 76, no. 8, 25 August 2004 (2004-08-25), pages 1114, XP002997748 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008099448A1 (fr) * 2007-02-09 2008-08-21 Masayoshi Yamaguchi Agent préventif/thérapeutique pour les maladies diabétiques
JP2011063554A (ja) * 2009-09-18 2011-03-31 Tokyo Univ Of Marine Science & Technology アディポネクチン分泌調節剤
US10076507B1 (en) 2011-07-15 2018-09-18 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
US10383837B2 (en) 2011-07-15 2019-08-20 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
US9943517B2 (en) 2012-11-13 2018-04-17 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
US10646489B2 (en) 2012-11-13 2020-05-12 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism

Also Published As

Publication number Publication date
JP4785140B2 (ja) 2011-10-05
JPWO2006013750A1 (ja) 2008-07-31

Similar Documents

Publication Publication Date Title
Fontanari et al. Cholesterol-lowering effect of whole lupin (Lupinus albus) seed and its protein isolate
Ryan Bioactive food components and health properties of rice bran
Plate et al. Cholesterol-lowering effect of extruded amaranth (Amaranthus caudatus L.) in hypercholesterolemic rabbits
Amad et al. Effects of a phytogenic feed additive on growth performance, selected blood criteria and jejunal morphology in broiler chickens.
Huang et al. The effect of adlay oil on plasma lipids, insulin and leptin in rat
AU2007235419A1 (en) Feed formulations containing docosahexaenoic acid
Wiklund et al. Fatty acid composition of M. longissimus lumborum, ultimate muscle pH values and carcass parameters in reindeer (Rangifer tarandus tarandus L) grazed on natural pasture or fed a commercial feed mixture
DE69832520T2 (de) Verwendung von konjugierten linoleinsäure zur behandlung von type ii diabetes
CN105661079A (zh) 用于体重减轻与保持的宠物食品组合物和方法
Santoso et al. Effect of Sauropus androgynus (Katuk) extract on egg production and lipid metabolism in layers
JP2009291187A (ja) 食生活改善用食品組成物
Porcino et al. Review on alternative meals for gilthead seabream, Sparus aurata
Hoi et al. Sorghum distillers dried grain lipid extract increases cholesterol excretion and decreases plasma and liver cholesterol concentration in hamsters
Sulistyowati et al. Quality of milk fatty acid during late lactation in dairy goat fed on PUFA-diet supplemented with yeast and
WO2006013750A1 (fr) Matiere alimentaire ayant un effet de regulation du metabolisme des lipides, aliment dietetique, nourriture pour animaux et procede pour nourrir un animal
Rouag et al. The effect of oral gavage (force-feeding) administration of fenugreek seeds (Trigonella foenum-graecum L.) on biochemical and neurobehavioural parameters in male Wistar rats
CN101045055A (zh) 含哌可酸的抗糖尿病组合物
Chen et al. A mixed animal and plant protein source replacing fishmeal affects bile acid metabolism and apoptosis in largemouth bass (Micropterus salmoides)
Sanchez-Muniz et al. Prevention of dietary hypercholesterolemia in rats using sunflower-oil-fried sardines. Effects on cholesterol and serum enzymes
Suruga et al. Okara” a new preparation of food material with antioxidant activity and dietary fiber from soybean
Sbardella et al. Rice oil as a soybean oil replacement in weanling pig diets
Utama et al. Utilization of dietary maggot frass on the performance, carcass percentage, digestive organs, and economic value of muscovy ducks
Hu et al. Nutritional evaluation of genetically modified rice expressing human lactoferrin gene
WO2003022295A1 (fr) Procede de maintien et de perte de poids pour animaux
Ju Can flaxseed lower cholesterol levels?

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006531398

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase